Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967758 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Safety and Immunogenicity of ADU-623
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01967758 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 11 participants.
The verdict
NCT01967758, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a study for patients with brain tumors called astrocytic tumors. The study will enroll patients who have received standard treatment. The study will test a vaccine called ADU-623. ADU-623 has not been tested in humans before, so the goal of this study is to see if ADU-623 can be given safely to brain cancer patients and what is the better dose to give patients among the three doses that planned to be tested. This study will also evaluate the length of time before patients' cancer worsens and if ADU-623 helps patients to live longer. The study will also measure the body's immune system response to ADU-623.
Interventions
- DRUG Antibiotics
- BIOLOGICAL Cohort 1
- BIOLOGICAL Cohort 3
- BIOLOGICAL Cohort 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-01-08 |
| Est. Completion | 2018-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01967758
The ClinicalTrials.gov registry entry for NCT01967758 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Antibiotics is the first listed.
NCT01967758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01967758 about?
NCT01967758 is a clinical study titled "Phase I Study of Safety and Immunogenicity of ADU-623". This is a study for patients with brain tumors called astrocytic tumors. The study will enroll patients who have received standard treatment. The study will test a vaccine called ADU-623. ADU-623 has not been tested in humans before, so the goal of this study is to see if ADU-623 can be given safely...
What is the current status of trial NCT01967758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2014-01-08. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT01967758?
The interventions under investigation include: Antibiotics (DRUG), Cohort 1 (BIOLOGICAL), Cohort 3 (BIOLOGICAL), Cohort 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01967758?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.